Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer.

Autor:	Candelaria RP; Department of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: rcandelaria@mdanderson.org., Adrada BE; Department of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lane DL; Department of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Rauch GM; Department of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Moulder SL; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Thompson AM; Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bassett RL; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Arribas EM; Department of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Le-Petross HT; Department of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Leung JWT; Department of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Spak DA; Department of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ravenberg EE; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., White JB; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Valero V; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yang WT; Department of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jazyk:	angličtina
Zdroj:	Ultrasound in medicine & biology [Ultrasound Med Biol] 2022 Jun; Vol. 48 (6), pp. 1010-1018. Date of Electronic Publication: 2022 Mar 14.
DOI:	10.1016/j.ultrasmedbio.2022.01.018
Abstrakt:	This study aimed to investigate mid-treatment breast tumor ultrasound characteristics that may predict eventual pathologic complete response (pCR) in triple-negative breast cancer; specifically, we examined associations between pCR and two parameters: tumor response pattern and tumor appearance. Ultrasound was performed at mid-treatment, defined as the completion of four cycles of anthracycline-based chemotherapy and before receiving taxane-based chemotherapy. Consensus imaging review was performed while blinded to pathology results (i.e., pCR/non-pCR) from surgery. Tumor response pattern was described as "complete," "concentric," "fragmented," "stable" or "progression." Tumor appearance was designated as "mass," "architectural distortion," "flat tumor bed" or "clip only." Univariate and multivariate regression analyses of 144 participants showed significant associations between mid-treatment response pattern and pCR (p = 0.0348 and p = 0.0173, respectively), with complete and concentric response patterns more likely to achieve pCR than other patterns. Univariate and multivariate regression analyses further showed significant associations between mid-treatment tumor appearance and pCR (p < 0.0001 for both), with persistent appearance of mass less likely than other appearances to achieve pCR. To conclude, our study demonstrated strong associations between pCR and both tumor response pattern and tumor appearance, thereby suggesting that these parameters have potential as qualitative imaging biomarkers of pCR in triple-negative breast cancer. Competing Interests: Acknowledgments Editorial support was provided by Bryan Tutt in Scientific Publications Services, Research Medical Library, at the University of Texas MD Anderson Cancer Center. This research was the subject of a scientific oral presentation at the 2019 Radiological Society of North America Scientific Assembly and National Meeting, Chicago, Illinois. This study was supported in part by the National Institutes of Health/National Cancer Institute under award No. P30 CA016672, the University of Texas MD Anderson Cancer Center Breast Cancer Moonshot Program and a CPRIT Multi-Investigator Research Award (MIRA): RP160710-C1-CPRIT. Conflict of interest disclosure G.M.R. has received research support from GE Healthcare research funding. E.M.A. is an advisory-board member and shareholder of Volumetric, Inc. J.W.T.L. is an advisory-board member for CureMetrix and for Subtle Medical and is on the speaker's bureau for Fujifilm. W.T.Y. receives textbook royalties from Elsevier. All other authors have no disclosures to declare. (Copyright © 2022 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu